Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy

FHS
May 29, 2024
7:03 pm

Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.

Curaleaf Q1 Revenue Growth Stalls

First quarter 2024 revenue of $339 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48% First quarter 2024 adjusted EBITDA(1) of

May 10, 2024

Actually Wegovy is good for dialysis companies, dialysis provider says

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian

February 21, 2024

Patient with rare neurodegenerative disorder improves with non-profit’s ASO therapy – Pharmaceutical Technology

Researchers at the non-profit n-Lorem discovered and developed a personalised ASO therapy to treat a rare neurological disease. Credit: SurfsUp via Shutterstock. A patient with

August 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.